Back to Peptides
CognitiveMedium Risk

Cerebrolysin

Also known as: FPF 1070, EBEWE Cerebrolysin

Half-life:
Varies by component

Administration Routes

intravenousintramuscular injection
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity

A standardized neuropeptide mixture with neurotrophic factor-like activity. Widely used in Europe and Asia for stroke recovery, Alzheimer's disease, and cognitive enhancement.

Primary Research Areas

  • neuroprotection
  • neuroplasticity
  • memory improvement
  • cognitive recovery

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyInvestigational

Neuropeptide mixture approved in EU/Asia but NOT FDA-approved. Phase 2/3 US trials for Alzheimer's disease and stroke with active IND. No NDA filed. Research use in US.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Cerebrolysin